Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1

2023年06月28日 20:45:12 来自: (0)参与

Up to 40% of people who reached the highest two doses of survodutide (BI 456906) achieved a weight loss of at least 20%1
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite2
Detailed data were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.

The Phase II study included two analyses: planned (assigned dose at randomization, which was also the primary endpoint) and actual (dose at the end of treatment).1 People who completed the study on the 4.8 mg dose (actual treatment analysis) achieved nearly 19% weight loss.1 As previously announced, the planned treatment analysis demonstrated nearly 15% weight loss for all those randomized to the 4.8 mg dose.1 Bodyweight reductions with survodutide had not reached a plateau at week 46, suggesting additional weight loss could be achieved with longer treatment duration.1

“Given the prevalence of obesity and its many disease-related complications, there is a dire need for treatments that can help treat the disease of obesity effectively,” said Carel le Roux, MD, Ph.D., Professor at University College in Dublin, Ireland, and Principal Investigator of the trial. “Current treatments for obesity mainly focus on weight loss by reducing energy intake.2 By activating both the glucagon and GLP-1 receptors, survodutide may both inhibit appetite and improve energy expenditure, thereby helping to treat the disease of obesity.2 These encouraging data support the further study of survodutide in larger Phase III trials.”

After 46 weeks of treatment, up to 40% of people who reached the highest two doses of survodutide achieved a weight loss of at least 20%, versus 0% with placebo.1 Body weight loss of 15% or more was achieved by 67% of people who reached survodutide 4.8 mg versus 4.3% of those on placebo.1

Treatment with survodutide did not show unexpected safety or tolerability issues. Serious adverse events were reported by 4.2% of participants on survodutide versus 6.5% of those on placebo.1 Treatment discontinuation due to adverse events occurred in 24.6% and 3.9% of participants, respectively, mainly due to gastrointestinal adverse events.1 Most treatment discontinuations due to adverse events occurred during the rapid dose-escalation phase and may potentially be mitigated with more gradual dose escalation.1 The adverse events reported were similar to those expected with the GLP1-R agonist class of drugs.1

“With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver. We look forward to furthering our discussions with health authorities to advance this dual receptor agonist into Phase III trials as we aim to help fill a treatment gap in this disease area.”

“Obesity is one of the most significant healthcare challenges in medicine today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma, we have both experience and success in discovering and developing peptide therapeutics that target key metabolic pathways – designed to help people living with overweight and obesity by achieving substantial weight loss while addressing the many complications of this disease.”

Please click on the following link for ‘Notes to editors’ and ‘References’

https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results

相关新闻
其它网友:美丽/mmmmm
评论:吃得苦中苦,才能开路虎;少年不努力,只能开夏利

天涯网友:過期愛仍等待
评论:我以为你只是颓废,原来你已经报废了。

本网网友:若凌° Provence -
评论:上联:该吃吃、该喝喝、有事别往心里搁。下联:泡泡澡、看看表、舒服一秒是一秒。横批:不能白活。

网易网友:别走停下来
评论:我谈过最长的恋爱,就是自恋

天猫网友:Sam| 绝情△
评论:真怀念小时候啊,天热的时候我也可以像男人一样光膀子。

百度网友:不要骗我了°
评论:我也想做一个优雅的淑女,是生活把老娘逼成了泼妇.

腾讯网友:我无力的趴下
评论:恋爱需要实习,而两个人分手则需要练习!

搜狐网友:凝固旳悲伤※
评论:我知道强扭的瓜不甜,但是本人就是不喜欢吃甜瓜。

猫扑网友:斑驳 wounded
评论:赚钱像接露水那么辛苦,花钱却像流水那么迅速

淘宝网友:多愁善感 mature°
评论:每个人出生时都是原创的,但可悲的是,很多人渐渐活成了盗版的。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin